Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Key Points

• Urogen Pharma missed quarterly EPS estimates, reporting a loss of $0.28 per share versus the expected $0.26 loss, while revenue of $72.46 million exceeded the $63.55 million consensus.
• ZUSDURI revenue surged 73% sequentially to $50.4 million, supported by growing prescriber adoption and repeat usage. The company also reported durable clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months.
• Urogen maintained its 2026 JELMYTO revenue guidance but raised full-year operating expense guidance to $260 million-$270 million as it increases ZUSDURI promotional spending and advances its pipeline, potentially pressuring near-term profitability.

Urogen Pharma (NASDAQ:URGN - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02), FiscalAI reports. The business had revenue of $72.46 million during the quarter, compared to analysts' expectations of $63.55 million.

Here are the key takeaways from Urogen Pharma's conference call:

• ZUSDURI revenue reached $50.4 million in Q2, up 73% sequentially, with 1,444 activated accounts, 452 prescribers, and repeat prescribers representing approximately 45% of writers. Community practices accounted for about 55% of utilization, supporting the company’s view that adoption remains in an early growth phase.
• UroGen reported durable ZUSDURI clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months and median response duration not yet reached. Management said real-world physician experience is increasingly supporting use beyond patients who are poor surgical candidates.
• JELMYTO revenue was stable at $22 million, and the company maintained its 2026 guidance of $97 million to $101 million. However, management has not yet observed a meaningful “reverse halo” effect from the ZUSDURI launch on JELMYTO demand.
• UroGen expects to submit the UGN-103 NDA within weeks, complete UGN-104 enrollment by year-end, and begin a UGN-501 Phase I study later in 2026. A patent allowance covering ZUSDURI and UGN-103 is expected to provide protection through July 2044.
• Full-year operating expense guidance increased to $260 million-$270 million as UroGen accelerates ZUSDURI promotional and patient-awareness spending and advances pipeline programs. Management remains confident it can reach profitability with existing capital resources, but the higher investment is expected to pressure near-term results.

Urogen Pharma Price Performance

URGN traded up $5.17 during mid-day trading on Wednesday, hitting $45.09. The stock had a trading volume of 1,818,843 shares, compared to its average volume of 791,040. The stock's fifty day simple moving average is $35.39 and its 200-day simple moving average is $26.61. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -16.36 and a beta of 1.57. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $47.84.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares of the company's stock, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Urogen Pharma

A number of large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after buying an additional 1,653 shares during the period. Main Street Financial Solutions LLC increased its position in shares of Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after acquiring an additional 1,968 shares in the last quarter. Barclays PLC raised its holdings in shares of Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company's stock worth $1,352,000 after acquiring an additional 2,125 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock worth $50,000 after acquiring an additional 3,070 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company's stock valued at $66,000 after acquiring an additional 3,125 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. HC Wainwright reissued a "buy" rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Oppenheimer increased their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an "outperform" rating in a report on Thursday, July 16th. Jefferies Financial Group raised shares of Urogen Pharma to a "strong-buy" rating in a report on Friday, April 24th. Finally, TD Cowen reiterated a "buy" rating on shares of Urogen Pharma in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.62.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source